Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal

Inclusion Criteria: 1. Diagnosis of nAMD 2. Male and Female patients with ≥40 years of age at index 3. Receipt of at least one injection of brolucizumab during the recruitment period 4. Signed written informed consent Exclusion Criteria: 1. Patients treated for RVO, DME, mCNV, and have diagnoses of diabetes-related macular degeneration within 6 months prior to the index date 2. Receipt of any anti-VEGF treatment other than brolucizumab in the study eye at index date 3. Central subfield of the study eye affected by fibrosis or geographic atrophy or total area of fibrosis \>50% of the total lesion in the study eye at Screening 4. Any active intraocular or periocular infection or active intraocular inflammation in either eye at index date 5. Patients who have been on anti-VEGF treatment for longer than 3 years (before index date) 6. Patients that have any contraindication and are not eligible for treatment with brolucizumab as according to the SmPC 7. Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the 24 months study participation 8. Patients participating in parallel in an interventional clinical trial 9. Patients participating in parallel in any other NIS generating primary data for an anti-VEGF drug 10. Retinal pigment epithelial rip/tear in the study eye at Screening or Baseline or current vitreous hemorrhage or history of vitreous hemorrhage in the study eye within 4 weeks prior to Baseline 11. Subretinal blood affecting the foveal center point and/or \>50% of the lesion of the study eye at Screening